MetLife Investment Advisors LLC Buys Shares of 13,791 Puma Biotechnology Inc (PBYI)

MetLife Investment Advisors LLC bought a new position in Puma Biotechnology Inc (NASDAQ:PBYI) during the 4th quarter, HoldingsChannel reports. The institutional investor bought 13,791 shares of the biopharmaceutical company’s stock, valued at approximately $1,363,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of PBYI. Nationwide Fund Advisors lifted its stake in Puma Biotechnology by 22.5% in the 3rd quarter. Nationwide Fund Advisors now owns 19,879 shares of the biopharmaceutical company’s stock worth $2,381,000 after purchasing an additional 3,657 shares in the last quarter. Sei Investments Co. purchased a new stake in Puma Biotechnology in the 3rd quarter worth approximately $256,000. New York State Common Retirement Fund lifted its stake in Puma Biotechnology by 38.9% in the 3rd quarter. New York State Common Retirement Fund now owns 44,792 shares of the biopharmaceutical company’s stock worth $5,364,000 after purchasing an additional 12,545 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in Puma Biotechnology by 33.8% in the 3rd quarter. Bank of New York Mellon Corp now owns 182,298 shares of the biopharmaceutical company’s stock worth $21,832,000 after purchasing an additional 46,001 shares in the last quarter. Finally, Russell Investments Group Ltd. increased its holdings in shares of Puma Biotechnology by 11.4% in the 3rd quarter. Russell Investments Group Ltd. now owns 25,817 shares of the biopharmaceutical company’s stock worth $3,092,000 after buying an additional 2,635 shares during the last quarter. Institutional investors and hedge funds own 95.95% of the company’s stock.

How to Become a New Pot Stock Millionaire

Shares of NASDAQ:PBYI opened at $62.80 on Monday. The firm has a market capitalization of $2,368.82, a PE ratio of -8.00 and a beta of 0.15. Puma Biotechnology Inc has a one year low of $28.35 and a one year high of $136.90. The company has a debt-to-equity ratio of 0.91, a quick ratio of 1.79 and a current ratio of 1.82.

Puma Biotechnology (NASDAQ:PBYI) last released its earnings results on Thursday, March 1st. The biopharmaceutical company reported ($1.71) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.98) by $0.27. The business had revenue of $21.60 million for the quarter, compared to the consensus estimate of $20.83 million. During the same period in the prior year, the business posted ($1.22) EPS. research analysts expect that Puma Biotechnology Inc will post -4.07 EPS for the current fiscal year.

In related news, insider Alan H. Auerbach sold 10,692 shares of the stock in a transaction on Monday, January 22nd. The shares were sold at an average price of $92.75, for a total transaction of $991,683.00. Following the transaction, the insider now owns 4,155,931 shares of the company’s stock, valued at approximately $385,462,600.25. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, SVP Richard Paul Bryce sold 1,860 shares of the stock in a transaction on Monday, January 22nd. The shares were sold at an average price of $92.75, for a total transaction of $172,515.00. Following the transaction, the senior vice president now directly owns 25,379 shares in the company, valued at approximately $2,353,902.25. The disclosure for this sale can be found here. 21.10% of the stock is currently owned by company insiders.

PBYI has been the topic of a number of research analyst reports. Royal Bank of Canada decreased their price target on shares of Puma Biotechnology to $77.00 and set a “sector perform” rating on the stock in a report on Wednesday, January 24th. Credit Suisse Group decreased their price target on shares of Puma Biotechnology from $147.00 to $106.00 and set an “outperform” rating on the stock in a report on Wednesday, January 24th. Citigroup reissued a “buy” rating and issued a $164.00 price target on shares of Puma Biotechnology in a report on Wednesday, January 3rd. ValuEngine lowered shares of Puma Biotechnology from a “hold” rating to a “sell” rating in a report on Wednesday, January 3rd. Finally, Zacks Investment Research raised shares of Puma Biotechnology from a “sell” rating to a “hold” rating in a report on Friday, January 26th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and seven have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $103.11.

ILLEGAL ACTIVITY NOTICE: This story was first reported by Ticker Report and is the sole property of of Ticker Report. If you are reading this story on another site, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The original version of this story can be viewed at https://www.tickerreport.com/banking-finance/3342705/metlife-investment-advisors-llc-buys-shares-of-13791-puma-biotechnology-inc-pbyi.html.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.

Want to see what other hedge funds are holding PBYI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Puma Biotechnology Inc (NASDAQ:PBYI).

Institutional Ownership by Quarter for Puma Biotechnology (NASDAQ:PBYI)

Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Somewhat Positive News Coverage Somewhat Unlikely to Impact API Technologies  Share Price
Somewhat Positive News Coverage Somewhat Unlikely to Impact API Technologies Share Price
DigitalNote Price Hits $0.0140 on Top Exchanges
DigitalNote Price Hits $0.0140 on Top Exchanges
BitCoal  Price Tops $0.0209
BitCoal Price Tops $0.0209
Reviewing NGL Energy Partners  & Macquarie Infrastructure
Reviewing NGL Energy Partners & Macquarie Infrastructure
Comparing Encore Capital Group  & CPI Card Group
Comparing Encore Capital Group & CPI Card Group
Financial Survey: Research Frontiers  and Its Rivals
Financial Survey: Research Frontiers and Its Rivals


Leave a Reply

© 2006-2018 Ticker Report. Google+.